Introduction

The regulation of cannabis in the Philippines has long been governed by stringent anti-drug laws, reflecting the country's historically tough stance on narcotics. However, evolving global perspectives on medical cannabis—particularly its potential therapeutic benefits for conditions like chronic pain, epilepsy, and multiple sclerosis—have prompted domestic discussions and legislative efforts to reform existing prohibitions. This article examines the current legal framework surrounding medical cannabis in the Philippines, traces its historical development, analyzes pending legislation, and explores the broader implications for public health, law enforcement, and economic policy. As of January 2026, medical cannabis remains illegal for most purposes, but targeted reforms are under active consideration, signaling a potential shift toward regulated access for compassionate use.

Historical Context and Evolution of Cannabis Regulation

Cannabis regulation in the Philippines dates back to colonial influences but was solidified in the post-independence era through comprehensive drug control measures. The foundational law is Republic Act No. 9165, known as the Comprehensive Dangerous Drugs Act of 2002. This statute classifies cannabis (marijuana) as a dangerous drug under Schedule I, alongside substances like heroin and methamphetamine, deeming it to have no accepted medical use and a high potential for abuse. Under RA 9165, possession, cultivation, distribution, or use of cannabis is punishable by severe penalties, including life imprisonment and fines ranging from PHP 500,000 to PHP 10 million for larger quantities. The law also mandates rehabilitation for first-time offenders in certain cases but emphasizes eradication and prohibition over harm reduction.

Prior to RA 9165, earlier laws such as Republic Act No. 6425 (the Dangerous Drugs Act of 1972) similarly criminalized cannabis, influenced by the U.S.-led global war on drugs and the Philippines' alignment with international treaties like the 1961 Single Convention on Narcotic Drugs, as amended by the 1972 Protocol, and the 1988 United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. The Philippines is a signatory to these conventions, which require member states to control cannabis strictly, allowing exceptions only for medical and scientific purposes under regulated conditions.

Despite this prohibitive framework, limited exceptions have existed for research and compassionate use. The Philippine Food and Drug Administration (FDA) has, since 2014, allowed the importation of cannabidiol (CBD)-based products on a case-by-case basis for patients with severe epilepsy, following approvals for drugs like Epidiolex. This is facilitated through the FDA's Compassionate Special Permit (CSP) program, which requires a prescription from a licensed physician and documentation of the patient's condition. However, such permits are rare, bureaucratic, and do not extend to tetrahydrocannabinol (THC)-containing products, which remain fully banned due to their psychoactive properties.

The push for broader medical cannabis access gained momentum in the 2010s amid anecdotal evidence from patients and advocacy from groups like the Philippine Cannabis Compassionate Society (PCCS) and medical professionals. High-profile cases, such as parents seeking treatment for children with Dravet syndrome, highlighted the limitations of the current system and spurred calls for reform.

Current Legal Status

As of January 2026, the possession, use, cultivation, or distribution of cannabis for medical purposes remains illegal under RA 9165, except for the narrow CSP exemptions administered by the FDA. Key aspects of the current status include:

Prohibitions and Penalties: Any form of cannabis, including medical variants, is classified as a dangerous drug. Simple possession of less than 300 grams can result in 12 years to life imprisonment, while cultivation or manufacturing incurs mandatory life sentences. Medical intent does not serve as a defense in criminal proceedings, as courts have consistently upheld the absolute ban.
Limited Medical Access: The FDA's CSP allows importation of non-THC cannabis-derived pharmaceuticals (e.g., CBD oils) for specific debilitating conditions, but only after rigorous review. By 2025 estimates, fewer than 500 such permits have been issued since the program's inception, primarily for pediatric epilepsy cases. Locally produced or sourced cannabis is entirely prohibited, and patients must rely on expensive imports, often facing delays due to customs regulations.
Enforcement and Judicial Interpretation: The Philippine Drug Enforcement Agency (PDEA) and the Philippine National Police (PNP) enforce RA 9165 aggressively, with cannabis-related arrests comprising a significant portion of drug cases. Supreme Court rulings, such as in People v. Brodett (G.R. No. 225278, 2018), affirm that medical necessity is not a valid exemption without legislative authorization. However, some lower courts have shown leniency in sentencing for minor possession, reflecting shifting public attitudes.
International Obligations: The Philippines' adherence to UN drug conventions constrains domestic reforms. Any legalization must include safeguards to prevent diversion to illicit markets, such as strict licensing and tracking systems.

Public opinion has evolved, with surveys from the Social Weather Stations (SWS) in 2024 indicating that over 60% of Filipinos support medical cannabis legalization under medical supervision, up from 40% in 2018. This shift is attributed to increased awareness of global successes in countries like Canada, Thailand, and several U.S. states.

Pending Legislation

Legislative efforts to legalize medical cannabis have intensified in recent Congresses, with bills aiming to amend RA 9165 and establish a regulated framework. The most prominent pending measures as of January 2026 are:

House Bill No. 10439 (Medical Cannabis Act): Passed by the House of Representatives on third and final reading in February 2024, this bill seeks to legalize cannabis for medical and scientific purposes. Key provisions include:
- Establishing a Medical Cannabis Office (MCO) under the Department of Health (DOH) to oversee cultivation, distribution, and prescription.
- Allowing licensed physicians to prescribe cannabis for qualifying conditions, such as cancer, HIV/AIDS, glaucoma, PTSD, and chronic pain.
- Permitting domestic cultivation by licensed facilities, with strict security measures to prevent abuse.
- Prohibiting recreational use and imposing penalties for violations, while decriminalizing possession for approved patients. The bill emphasizes equity, including provisions for indigent patients to access subsidized treatments. However, it stalled in the Senate after referral to the Committee on Health in March 2024.
Senate Bill No. 2573: Filed by Senator Robinhood Padilla in September 2023, this companion measure mirrors HB 10439 but includes additional safeguards, such as mandatory THC limits in products and a national registry for patients. It proposes integrating medical cannabis into the Universal Health Care Act (RA 11223) for insurance coverage. As of January 2026, the bill remains pending at the committee level, with hearings ongoing amid debates over potential misuse and federalism concerns (e.g., local government units' roles in enforcement).
Other Related Bills: Senate Bill No. 180 (filed in 2022) and House Bill No. 6513 (from the 18th Congress, 2019) laid earlier groundwork but lapsed without passage. Recent proposals, like House Bill No. 12045 (2025), focus on hemp (low-THC cannabis) for industrial uses, which could indirectly support medical reforms by normalizing cannabis agriculture.

Challenges to passage include opposition from conservative lawmakers, religious groups, and anti-drug advocates who fear a "slippery slope" to recreational legalization. Proponents, including the DOH and the Philippine Medical Association, argue for evidence-based policy, citing studies from the World Health Organization (WHO) on cannabis's medical efficacy.

If enacted, these bills would require implementing rules and regulations (IRRs) from agencies like the DOH, FDA, and PDEA, potentially taking 6-12 months post-approval. Presidential veto remains a risk, though President Ferdinand Marcos Jr. has expressed openness to medical cannabis in 2024 statements, provided robust controls are in place.

Implications and Future Outlook

Legalizing medical cannabis could transform healthcare in the Philippines by providing alternative treatments for over 1 million patients with chronic illnesses, reducing reliance on opioids, and generating economic benefits through a new industry estimated at PHP 10-20 billion annually in taxes and jobs. However, risks include diversion to black markets, youth access, and strain on regulatory bodies.

Broader implications extend to criminal justice reform, potentially leading to amnesty for past medical-related convictions, and alignment with ASEAN trends (e.g., Thailand's 2022 decriminalization). Ongoing research at institutions like the University of the Philippines could bolster evidence for expanded uses.

While progress is evident, the timeline for enactment remains uncertain, hinging on Senate action and bicameral reconciliation. Stakeholders continue to advocate for balanced reforms that prioritize patient welfare without compromising anti-drug efforts.